Axepron Dosage/Direction for Use

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.
Parenteral routes of administration other than intravenous are not recommended.
Pantoprazole for injection may be administered intravenously through a dedicated line or through a Y-site. The intravenous line should be flushed before and after administration of pantoprazole for injection with either 5% dextrose injection, USP, 0.9% sodium chloride injection, USP, or lactated ringer's injection, USP. When administered through a Y-site, pantoprazole for injection is compatible with the following solutions: 5% dextrose injection, USP, 0.9% sodium chloride injection, USP, or lactated ringer's injection, USP.
Midazolam HCl has been shown to be incompatible with Y-site administration of pantoprazole for injection. Pantoprazole for injection may not be compatible with products containing zinc. When pantoprazole for injection is administered through Y-site, immediately stop use if precipitation or discoloration occurs.
Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis: Recommended Dosage: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days.
Administration and Preparation Instructions: Data on the safe and effective dosing for condition other than those described (see Indications) such as a life-threatening upper gastrointestinal bleeds, are not available. PANTOPRAZOLE 40 mg once daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions.
Fifteen Minutes Infusion: PANTOPRAZOLE for injection should be reconstituted with 10 mL 0.9 sodium chloride injection, USP, and further diluted (admixed) with 100 mL of 5% dextrose injection, USP, 0.9% sodium chloride injection, USP, or lactated ringer's injection, USP, to a final concentration of approximately 0.4 mg/mL. The reconstituted solution may be store up to 6 hours at room temperature prior to further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light. PANTOPRAZOLE for injection admixtures should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min.
Two Minutes Infusion: PANTOPRAZOLE for Injection should be reconstituted with 10 mL of 0.9% sodium chloride injection, USP, to a final concentration of approximately 4 mg/mL. The reconstituted solution may be stored for up to 24 hours at room temperatures prior to intravenously infusion and does not need to be protected from light. PANTOPRAZOLE for injection should be administered intravenously over a period of at least 2 minutes.
Pathological Hypersecretion including Zollinger-Ellison Syndrome: Recommended Dosage: The dosage of PANTOPRAZOLE for injection in patients with pathological hypersecretory conditions including Zollinger-Ellison syndrome varies with individual patients. The recommended adult dosage is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient's needs based on acid output measurements. In those patient who need a higher dosage, 80 mg intravenously every 8 hours is expected to maintain acid output below 10 mEq/h. Daily doses higher than 240 mg or administered for more than 6 days have not been studied. Transition from oral to intravenous and from intravenous to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of effect of acid suppression. Patients with Zollinger-Ellison syndrome may be vulnerable to serious clinical complications of increased acid production even after a short period of loss effective inhibition.
Administration and Preparation Instructions: Fifteen Minutes Infusion: Each vial of PANTOPRAZOLE for injection should be reconstituted with 10 mL of 0.9% sodium chloride injection, USP. The contents of two vials should be combined and further diluted (admixed) with 80 mL of 5% dextrose injection, USP, 0.9% sodium chloride injection, USP, or lactated ringer's injection, USP, to a total volume of 100 mL with a final concentration of approximately 0.8 mg/mL. The reconstituted solution may be stored for up to 6 hours at room temperature prior for further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light.
PANTOPRAZOLE for injection should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min.
Two Minutes Infusion: PANTOPRAZOLE for injection should be reconstituted with 10 mL of 0.9% sodium chloride injection, USP, per vial to a final concentration of approximately 4 mg/mL. The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light. The total volume from both vials should be administered intravenously over a period of at least 2 minutes.